BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
UBS
Colorcon
Citi
Johnson and Johnson
Merck
Novartis
Boehringer Ingelheim
Cipla
Dow

Generated: January 19, 2018

DrugPatentWatch Database Preview

Pfizer Inc Company Profile

« Back to Dashboard

What is the competitive landscape for PFIZER INC, and what generic alternatives to PFIZER INC drugs are available?

PFIZER INC has twelve approved drugs.

There are twenty-nine US patents protecting PFIZER INC drugs on PFIZER INC drugs in the past three years. There is one tentative approval on PFIZER INC drugs.

There are seven hundred and twenty-one patent family members on PFIZER INC drugs in seventy countries and forty-one supplementary protection certificates in thirteen countries.

Summary for Pfizer Inc
International Patents:721
US Patents:29
Tradenames:12
Ingredients:12
NDAs:12
Drug Master File Entries: 71

Drugs and US Patents for Pfizer Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Inc QUILLICHEW ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE, CHEWABLE;ORAL 207960-001 Dec 4, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Pfizer Inc IBRANCE palbociclib CAPSULE;ORAL 207103-001 Feb 3, 2015 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer Inc CAMPTOSAR irinotecan hydrochloride INJECTABLE;INJECTION 020571-001 Jun 14, 1996 AP RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Pfizer Inc IBRANCE palbociclib CAPSULE;ORAL 207103-002 Feb 3, 2015 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer Inc FRAGMIN dalteparin sodium INJECTABLE;SUBCUTANEOUS 020287-001 Dec 22, 1994 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Pfizer Inc TROXYCA ER naltrexone hydrochloride; oxycodone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 207621-005 Aug 19, 2016 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Pfizer Inc TROXYCA ER naltrexone hydrochloride; oxycodone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 207621-002 Aug 19, 2016 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Pfizer Inc VIAGRA sildenafil citrate TABLET;ORAL 020895-002 Mar 27, 1998 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Pfizer Inc QUILLICHEW ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE, CHEWABLE;ORAL 207960-003 Dec 4, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Pfizer Inc CHANTIX varenicline tartrate TABLET;ORAL 021928-001 May 10, 2006 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Pfizer Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer Inc FRAGMIN dalteparin sodium INJECTABLE;SUBCUTANEOUS 020287-001 Dec 22, 1994 ➤ Subscribe ➤ Subscribe
Pfizer Inc CAMPTOSAR irinotecan hydrochloride INJECTABLE;INJECTION 020571-001 Jun 14, 1996 ➤ Subscribe ➤ Subscribe
Pfizer Inc NICOTROL nicotine SPRAY, METERED;NASAL 020385-001 Mar 22, 1996 ➤ Subscribe ➤ Subscribe
Pfizer Inc VIAGRA sildenafil citrate TABLET;ORAL 020895-001 Mar 27, 1998 ➤ Subscribe ➤ Subscribe
Pfizer Inc VIAGRA sildenafil citrate TABLET;ORAL 020895-002 Mar 27, 1998 ➤ Subscribe ➤ Subscribe
Pfizer Inc FRAGMIN dalteparin sodium INJECTABLE;SUBCUTANEOUS 020287-003 Mar 18, 1996 ➤ Subscribe ➤ Subscribe
Pfizer Inc VIAGRA sildenafil citrate TABLET;ORAL 020895-003 Mar 27, 1998 ➤ Subscribe ➤ Subscribe
Pfizer Inc CAMPTOSAR irinotecan hydrochloride INJECTABLE;INJECTION 020571-002 Jun 14, 1996 ➤ Subscribe ➤ Subscribe
Pfizer Inc GEODON ziprasidone hydrochloride SUSPENSION;ORAL 021483-001 Mar 29, 2006 ➤ Subscribe ➤ Subscribe
Pfizer Inc FRAGMIN dalteparin sodium INJECTABLE;SUBCUTANEOUS 020287-004 Jan 30, 1998 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for PFIZER INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 11 mg ➤ Subscribe 11/7/2016
➤ Subscribe Tablets 0.5 mg and 1 mg ➤ Subscribe 5/10/2010
➤ Subscribe Capsules 20 mg, 40 mg, 60 mg and 80 mg ➤ Subscribe 2/7/2005
➤ Subscribe Tablets 25 mg and 50 mg ➤ Subscribe 11/19/2004
➤ Subscribe Tablets 100 mg ➤ Subscribe 10/25/2004
➤ Subscribe Injection 20 mg/mL, 2 mL and 5 mL vials ➤ Subscribe 7/26/2004

Non-Orange Book US Patents for Pfizer Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,062,667 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
5,710,304 GABA and L-glutamic acid analogs for antiseizure treatment ➤ Subscribe
6,262,120 GABA and L-glutamic acid analogs for antiseizure treatment ➤ Subscribe
6,897,310 Aryl fused azapolycyclic compounds ➤ Subscribe
5,563,175 GABA and L-glutamic acid analogs for antiseizure treatment ➤ Subscribe
7,205,300 Aryl fused azapolycyclic compounds ➤ Subscribe
6,951,938 Aryl fused azapolycyclic compounds ➤ Subscribe
8,956,649 Orally effective methylphenidate extended release powder and aqueous suspension product ➤ Subscribe
6,117,906 GABA and L-glutamic acid analogs for antiseizure treatment ➤ Subscribe
9,675,704 Modified release formulations containing drug-ion exchange resin complexes ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Pfizer Inc Drugs

Supplementary Protection Certificates for Pfizer Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
5 Finland ➤ Subscribe
2017 00010 Denmark ➤ Subscribe PRODUCT NAME: PALBOCICLIB, EVENTUELT I FORM AF EN FARMACEUTISK ACCEPTABEL ESTER ELLER ET FARMACEUTISK ACCEPTABELT SALT, AMID ELLER PRODRUG; REG. NO/DATE: EU/1/16/1147/001-006 20161111
1999 Austria ➤ Subscribe PRODUCT NAME: ''SILDENAFIL'' UND DESSEN PHARMAZEUTISCH ANNEHMBAREN SALZE, EINSCHLIESSLICH DES CITRATS; NAT. REGISTRATION NO/DATE: EU/1/98/077/001 - EU/1/98/077/012 19980914; FIRST REGISTRATION: LI 54642 01-54642 03 19980622
2008010 Lithuania ➤ Subscribe PRODUCT NAME: VARENICLINUM TARTRAT; REG. NO/DATE: EU/1/06/360/001-010 20060926
2004 00036 Denmark ➤ Subscribe
0164 Netherlands ➤ Subscribe 300164, 20130518, EXPIRES: 20180517
0641330/01 Switzerland ➤ Subscribe FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
0170012 00212 Estonia ➤ Subscribe PRODUCT NAME: PALBOTSIKLIIB;REG NO/DATE: EU/1/16/1147 11.11.2016
2017013 Lithuania ➤ Subscribe PRODUCT NAME: PALBOCIKLIBAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS, ESTERIO, AMIDO ARBA PROVAISTO PAVIDALU; REGISTRATION NO/DATE: EU/1/16/1147 20161109
2008000038 Germany ➤ Subscribe PRODUCT NAME: VARENICLIN GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES UNTER EINSCHLUSS VON TARTRAT; REGISTRATION NO/DATE: EU/1/06/360/001-010 20060926
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Mallinckrodt
Cantor Fitzgerald
Argus Health
UBS
Julphar
Queensland Health
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot